Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.

Primary objective: To evaluate the pharmacokinetic similarity of a single fasting subcutaneous injection of 100 μg of recombinant human parathyroid hormone (1-84) for injection [rhPTH (1-84), specification: 100 μg/bottle] in healthy Chinese subjects before and after the change of production site. Secondary objectives: 1. To observe the safety of recombinant human parathyroid hormone (1-84) for injection in healthy Chinese subjects before and after the change of production site; 2. To observe the immunogenicity of recombinant human parathyroid hormone (1-84) for injection in healthy Chinese subjects before and after the change of production site; 3. To observe the changes in serum total calcium (albumin corrected) concentration after a single subcutaneous injection of 100 μg of recombinant human parathyroid hormone (1-84) for injection in healthy Chinese subjects before and after the change of production site.

Primary objective: To observe the pharmacokinetic characteristics of the investigational recombinant human parathyroid hormone (1-84) for injection (specification: 100 μg/bottle; manufacturer: Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.) and the reference drug recombinant human parathyroid hormone (1-84) (trade name: Natpar®, specification: 50 μg/dose; manufacturer: Shire Pharmaceuticals Ireland Limited) after a single subcutaneous injection in healthy Chinese subjects, and to evaluate the pharmacokinetic similarity of the two preparations. Secondary objectives: 1. To observe the safety of the investigational recombinant human parathyroid hormone (1-84) and the reference drug Natpar® in healthy Chinese subjects; 2. To observe the immunogenicity of the investigational recombinant human parathyroid hormone (1-84) and the reference drug Natpar® in healthy Chinese subjects; 3. To observe the changes in serum total calcium (albumin corrected) concentration after a single subcutaneous injection of 50 μg of the investigational recombinant human parathyroid hormone (1-84) and the reference drug Natpar® in healthy Chinese subjects.

1. Evaluate the safety and tolerability of BC008-1A injection in subjects with advanced solid tumors; 2. Explore the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of BC008-1A injection in subjects with advanced solid tumors;